<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02157584</url>
  </required_header>
  <id_info>
    <org_study_id>LX1606.1-107-NRM</org_study_id>
    <secondary_id>LX1606.107</secondary_id>
    <nct_id>NCT02157584</nct_id>
  </id_info>
  <brief_title>An Open-Label Food Effect Study of Telotristat Etiprate</brief_title>
  <official_title>A Phase 1, Randomized, Single Center, Open Label, 2 Sequence, 2 Period, Crossover Study to Evaluate the Effect of Food on the Single Dose Pharmacokinetics of Telotristat Etiprate (LX1606 Hippurate) in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the effect of food on the pharmacokinetics (PK) of
      telotristat ethyl and its metabolite LP-778902 relative to administration of single dose
      telotristat etiprate in the fasted state in healthy adult male and female subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of telotristat ethyl</measure>
    <time_frame>Days 1, 2, 3, 6, 7, 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of metabolite LP-778902</measure>
    <time_frame>Days 1, 2, 3, 6, 7, 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) on Day 1 in a fed condition. Days 2 to 5 will be Washout Days. On Day 6, subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) 1 in a fasted condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) on Day 1 in a fasted condition. Days 2 to 5 will be Washout Days. On Day 6, subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) 1 in a fed condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telotristat etiprate</intervention_name>
    <description>2 × 250 mg (as free base) telotristat etiprate tablets (fed conditions /high-fat / high caloric meal)</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telotristat etiprate</intervention_name>
    <description>2 × 250 mg (as free base) telotristat etiprate tablets (fasted conditions)</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult subjects aged ≥18 to ≤55 years of age at screening

          -  Body mass index ≥18.0 to ≤32.0 kg/m^2

          -  Acceptable vital signs at Screening: Systolic blood pressure = 90-140 mm Hg, Diastolic
             blood pressure = 50-90 mm Hg, Heart rate = 40-100 beats per minute

          -  Able and willing to ingest an entire high fat/high caloric breakfast meal within 30
             minutes

          -  Willingness to adhere to the restrictions outlined in the protocol

          -  Able to comprehend and sign the Informed Consent Form

        Exclusion Criteria:

          -  Presence of any clinically significant physical, laboratory, or ECG finding that may
             interfere with the study in the opinion of the Investigator

          -  Use of any medications, herbal tea, energy drink, herbal products, or supplements
             within 14 days of study start

          -  Receipt of any investigational agent or study drug within 30 days or 5 half-lives
             prior to Screening

          -  Receipt of any protein- or antibody-based therapeutic agent within 3 months prior to
             Screening

          -  Prior exposure to telotristat etiprate

          -  Use of tobacco, smoking cessation products, or nicotine products within 3 months prior
             to Screening

          -  History of major surgery within 6 months prior to Screening

          -  History of any GI surgery that may induce malabsorption

          -  History of renal disease, or significantly abnormal glomerular filtration rate (&lt;90
             mL/min as calculated using the Cockcroft-Gault equation) at Screening

          -  History of hepatic disease, or significantly abnormal liver function tests at
             Screening

          -  History of any clinically significant psychiatric, renal, hepatic, pancreatic,
             cardiovascular, neurological, endocrinologic, hematological, or GI abnormality

          -  History of any active infection within 14 days prior to Screening

          -  History of alcohol or substance abuse within 2 years prior to Screening

          -  Positive hepatitis panel (including hepatitis B surface antigen and hepatitis C virus
             antibody) or positive human immunodeficiency virus antibody screens

          -  Concurrent conditions that could interfere with safety and/or tolerability
             measurements

          -  Donation or loss of &gt;500 mL of blood or blood product within 3 months prior to
             Screening

          -  Women who are breastfeeding or are planning to become pregnant during the study

          -  Positive serum pregnancy test (females only)

          -  Positive urine screen for selected drugs of abuse and cotinine

          -  Consumption of alcohol within 48 hours prior to study start

          -  Consumption of caffeine- and/or xanthine-containing products within 72 hours of study
             start

          -  Consumption of grapefruit, Seville oranges, and grapefruit- or Seville
             orange-containing products within 72 hours prior to study start

          -  Unable or unwilling to communicate or cooperate with the Investigator for any reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suman Wason, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2014</study_first_submitted>
  <study_first_submitted_qc>June 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2014</study_first_posted>
  <last_update_submitted>September 5, 2014</last_update_submitted>
  <last_update_submitted_qc>September 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

